Drugs / TLC19
TLC19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04697654 | Oct 2020 → Jun 2021 | COVID-19 | Taiwan Liposome Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLC19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04697654 ↗ |
| Known as | TLC19 (Hydroxychloroquine Liposome Inhalation Suspension) | “TLC19 (Hydroxychloroquine Liposome Inhalation Suspension)” NCT04697654 ↗ |